Disease · MONDO_0012817
Comparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 25
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A (Combination Chemotherapy) vs Arm B (Combination Chemotherapy, Topotecan Hydrochloride): deaths from any cause | 51 of 308 | 42 of 318 | 626 | NCT01231906 | Trial comparisons |
| Arm A (Combination Chemotherapy) vs Arm B (Combination Chemotherapy, Topotecan Hydrochloride): serious adverse events | 8 of 308 | 11 of 318 | 626 | NCT01231906 | Trial comparisons |
| Regimen A (VDC/IE) vs Regimen B (VDC/IE + Ganitumab): deaths from any cause | 61 of 145 | 67 of 150 | 295 | NCT02306161 | Trial comparisons |
| Regimen A (VDC/IE) vs Regimen B (VDC/IE + Ganitumab): serious adverse events | 3 of 145 | 45 of 150 | 295 | NCT02306161 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: Incidence of Adverse Events | 45 of 45 | 45 of 45 | 90 | NCT02243605 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: deaths from any cause | 42 of 45 | 37 of 45 | 90 | NCT02243605 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: serious adverse events | 30 of 45 | 31 of 45 | 90 | NCT02243605 | Trial comparisons |
| Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide: deaths from any cause | 15 of 30 | 8 of 16 | 46 | NCT05440786 | Trial comparisons |
| Arm A: VACdxr With ImmTher vs Arm B: VACdxr: serious adverse events | 1 of 31 | 0 of 14 | 45 | NCT00038142 | Trial comparisons |
| Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide: serious adverse events | 12 of 30 | 5 of 15 | 45 | NCT05440786 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: Toxicity | 6 of 6 | 24 of 26 | 32 | NCT00923351 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: deaths from any cause | 0 of 6 | 1 of 26 | 32 | NCT00923351 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: serious adverse events | 6 of 6 | 12 of 26 | 32 | NCT00923351 | Trial comparisons |
Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay | 0 of 5 | 15 of 26 | 31 | NCT00923351 | Trial comparisons |
| Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 vs Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2: Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE) | 2 of 5 | 12 of 18 | 23 | NCT03245151 | Trial comparisons |
| Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 vs Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2: Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 5 of 5 | 18 of 18 | 23 | NCT03245151 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities | 1 of 10 | 0 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Laboratory Abnormalities | 0 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Physical Examination Abnormalities | 6 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: deaths from any cause | 6 of 10 | 2 of 3 | 13 | NCT05093322 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0012817/comparisons